Second-line therapy in colorectal cancer.

Berlin J
Oncology (Williston Park). 2000 14 (12 Suppl 11): 21-6

PMID: 11204658

Second-line therapy is a relatively new concept for gastrointestinal oncologists. Although retreatment with fluorouracil (5-FU) is common, offering colorectal cancer patients a different chemotherapeutic agent as second-line therapy is a fairly recent strategy. The focus of this article is on the use and efficacy of oxaliplatin (Eloxatin) as second-line therapy for colorectal cancer. As such, this article will present very limited data on the toxicity of oxaliplatin regimens.

MeSH Terms (14)

Antineoplastic Combined Chemotherapy Protocols Camptothecin Clinical Trials, Phase II as Topic Colorectal Neoplasms Fluorouracil Humans Infusions, Intravenous Irinotecan Leucovorin Neoplasm Staging Organoplatinum Compounds Oxaliplatin Survival Analysis Treatment Outcome

Connections (1)

This publication is referenced by other Labnodes entities: